Effects of treatments in autoimmune encephalitis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study follows patients with autoimmune encephalitis (brain inflammation caused by the immune system) to see how treatments affect them in the medium term. It may help doctors learn which treatments work best for people with this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child have been diagnosed with autoimmune encephalitis, specifically with antibodies against certain proteins (like GAD, NMDAR, LGI1, CASPR2, IgLON5, or GFAP).
- You have not started treatment yet, or started treatment within the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows adults with NMDAR encephalitis over time to understand its long-term effects. It uses online questionnaires, so you need internet access at home.
This study looks at how the immune system works in certain neurological conditions, including autoimmune encephalitis and related nerve disorders. Researchers may use blood and/or spinal fluid samples, especially when antibodies are present or can’t be found, to better understand what’s driving the illness.
This study is for people with autoimmune encephalitis, a condition where the immune system attacks the brain. It aims to collect information about this disease to learn more about it and how to treat it.
This research study looks for new markers in the blood of people with autoimmune encephalitis (a condition where the immune system attacks the brain). It aims to better understand what causes the disease and find new ways to diagnose it.
This study follows people newly diagnosed with anti-LGI1 encephalitis (a brain inflammation) to see how well they do over time. It aims to learn more about the condition and improve care.
This trial tests a new drug called Taitacept for people with autoimmune encephalitis (brain inflammation caused by the immune system) that has not improved with standard treatments or has returned. The goal is to see if Taitacept can help control symptoms.
Hear when a new GFAP trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.